Advanced Hodgkin's lymphoma: End-of-treatment FDG-PET should be maintained

Elif Hindié¹, Charles Mesguich², Krimo Bouabdallah³, Noël Milpied³

Affiliations

¹ Department of Nuclear Medicine, Bordeaux University Hospital, Bordeaux, France. elif.hindie@chu-bordeaux.fr.
² Department of Nuclear Medicine, Bordeaux University Hospital, Bordeaux, France.
³ Department of Hematological Oncology, Bordeaux University Hospital, Bordeaux, France.

PMID: 28466283
DOI: 10.1007/s00259-017-3714-4

Editorial

Advanced Hodgkin's lymphoma: End-of-treatment FDG-PET should be maintained

Elif Hindié et al. Eur J Nucl Med Mol Imaging. 2017 Aug.

. 2017 Aug;44(8):1254-1257.

doi: 10.1007/s00259-017-3714-4.

Authors

Elif Hindié¹, Charles Mesguich², Krimo Bouabdallah³, Noël Milpied³

Affiliations

¹ Department of Nuclear Medicine, Bordeaux University Hospital, Bordeaux, France. elif.hindie@chu-bordeaux.fr.
² Department of Nuclear Medicine, Bordeaux University Hospital, Bordeaux, France.
³ Department of Hematological Oncology, Bordeaux University Hospital, Bordeaux, France.

PMID: 28466283
DOI: 10.1007/s00259-017-3714-4

No abstract available

PubMed Disclaimer

Comment in

Response to the letter by Adams and Kwee, entitled: "Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma".
Hindié E, Mesguich C, Bouabdallah K, Milpied N. Hindié E, et al. Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1937-1939. doi: 10.1007/s00259-017-3773-6. Eur J Nucl Med Mol Imaging. 2017. PMID: 28707119 No abstract available.
Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma.
Adams HJA, Kwee TC. Adams HJA, et al. Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1934-1936. doi: 10.1007/s00259-017-3771-8. Eur J Nucl Med Mol Imaging. 2017. PMID: 28707121 No abstract available.

Comment on

US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. Press OW, et al. J Clin Oncol. 2016 Jun 10;34(17):2020-7. doi: 10.1200/JCO.2015.63.1119. Epub 2016 Apr 11. J Clin Oncol. 2016. PMID: 27069074 Free PMC article. Clinical Trial.
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.
Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S. Johnson P, et al. N Engl J Med. 2016 Jun 23;374(25):2419-29. doi: 10.1056/NEJMoa1510093. N Engl J Med. 2016. PMID: 27332902 Free PMC article. Clinical Trial.

References

1. Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1095-105 - PubMed
1. J Nucl Med. 2015 Jan;56(1):38-44 - PubMed
1. J Clin Oncol. 2007 Feb 10;25(5):579-86 - PubMed
1. J Clin Oncol. 2014 Sep 20;32(27):3059-68 - PubMed
1. Cancer Med. 2016 Mar;5(3):398-406 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Advanced Hodgkin's lymphoma: End-of-treatment FDG-PET should be maintained

Affiliations

Advanced Hodgkin's lymphoma: End-of-treatment FDG-PET should be maintained

Authors

Affiliations

Comment in

Comment on

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical